MurphyMJ, CohenJM, VeselyMD, et al.Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis. J Am Acad Dermatol. 2022; 86(5):1080–1091.
2.
FloudasA, SaundersSP, MoranT, et al.IL-17 receptor A maintains and protects the skin barrier to prevent allergic skin inflammation. J Immunol. 2017; 199(2):707–717.
3.
DavidsonL, van den ReekJMPA, BrunoM, et al.Risk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sources. Lancet Reg Health Eur. 2021; 13:100266.
4.
TanQ, YangH, LiuE, et al.P38/ERK MAPK signaling pathways are involved in the regulation of filaggrin and involucrin by IL-17. Mol Med Rep. 2017; 16(6):8863–8867.
5.
NakashimaC, YanagiharaS, OtsukaA. Innovation in the treatment of atopic dermatitis: emerging topical and oral Janus kinase inhibitors. Allergol Int. 2022; 71(1):40–46.
